Resistant Hypertension: Mineralocorticoid Receptor Antagonist or Renal Denervation?

Hypertension

Volumn 67, Issue 2, 2016, Pages 278-280

  Carey, Robert M ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISOPROLOL; BRAIN NATRIURETIC PEPTIDE; CHLORTALIDONE; DOXAZOSIN; LOOP DIURETIC AGENT; MINERALOCORTICOID ANTAGONIST; MINERALOCORTICOID RECEPTOR; NORMETADRENALIN; PLACEBO; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; TORASEMIDE;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CONGESTIVE HEART FAILURE; DIURETIC THERAPY; DRUG TREATMENT FAILURE; END STAGE RENAL DISEASE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY DENERVATION; KIDNEY FAILURE; MEDICATION COMPLIANCE; NOTE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESISTANT HYPERTENSION; WHITE COAT HYPERTENSION; BLOOD PRESSURE; FEMALE; INNERVATION; KIDNEY; MALE; PHYSIOLOGY; PROCEDURES; SYMPATHECTOMY;

BLOOD PRESSURE; FEMALE; HUMANS; HYPERTENSION; KIDNEY; MALE; SPIRONOLACTONE; SYMPATHECTOMY;

EID: 84954391721     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.115.06616     Document Type: Note

References (11)

1. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, White W, Sica D, Ferdinand K, Giles TD, Falkner B, Carey RM. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008;51:1403-1419. doi: 10.1161/HYPERTENSIONAHA.108.189141.
2. Rosa J, Widimský P, Waldauf P, et al. Role of adding spironolactone and renal denervation in true resistant hypertension: one-year outcomes of randomized PRAGUE-15 study. Hypertension. 2016;67:397-403. doi: 10.1161/HYPERTENSIONAHA.115.06526.
3. Sarafidis PA, Georgianos P, Bakris GL. Resistant hypertension-its identification and epidemiology. Nat Rev Nephrol. 2013;9:51-58. doi: 10.1038/nrneph.2012.260.
4. White WB, Turner JR, Sica DA, Bisognano JD, Calhoun DA, Townsend RR, Aronow HD, Bhatt DL, Bakris GL. Detection, evaluation, and treatment of severe and resistant hypertension: proceedings from an American Society of Hypertension Interactive forum held in Bethesda, MD, U.S.A., October 10th 2013. J Am Soc Hypertens. 2014;8:743-757. doi: 10.1016/j. jash.2014.06.005.
5. Persell SD. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension. 2011;57:1076-1080. doi: 10.1161/HYPERTENSIONAHA.111.170308.
6. Sim JJ, Bhandari SK, Shi J, Reynolds K, Calhoun DA, Kalantar-Zadeh K, Jacobsen SJ. Comparative risk of renal, cardiovascular, and mortality outcomes in controlled, uncontrolled resistant, and nonresistant hypertension. Kidney Int. 2015;88:622-632. doi: 10.1038/ki.2015.142.
7. Dudenbostel T, Acelajado MC, Pisoni R, Li P, Oparil S, Calhoun DA. Refractory Hypertension: Evidence of Heightened Sympathetic Activity as a Cause of Antihypertensive Treatment Failure. Hypertension. 2015;66:126-133. doi: 10.1161/HYPERTENSIONAHA.115.05449.
8. Vaclavik J, Sedlak R, Jarkovsky J, Kocianovai E, Taborsky M. Effect of spironolactone in resistant arterial hypertension: a randomized, double-blind, placebo-controlled trial (ASPIRAJNT-EXT). Medicine. 2014;93:1-9.
9. Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, Ford I, Cruickshank JK, Caulfield MJ, Salsbury J, Mackenzie I, Padmanabhan S, Brown MJ; British Hypertension Society's PATHWAY Studies Group. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomized, double-blind, crossover trial. Lancet. 2015;386:2059-2068.
10. Bhatt DL, Kandzari DE, O'Neill WW, D'Agostino R, Flack JM, Katzen BT, Leon MB, Liu M, Mauri L, Negoita M, Cohen SA, Oparil S, Rocha-Singh K, Townsend RR, Bakris GL; SYMPLICITY HTN-3 Investigators. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370:1393-1401. doi: 10.1056/NEJMoa1402670.
11. Azizi M, Sapoval M, Gosse P, et al; Renal Denervation for Hypertension (DENERHTN) Investigators. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial. Lancet. 2015;385:1957-1965. doi: 10.1016/S0140-6736(14)61942-5.